Milestone Pharmaceuticals has announced positive results from the Phase 2 NODE-1 study of intranasal etripamil for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT), a type of cardiac arrhythmia. The double-blind dose ranging study enrolled 104 patients who received 1 of 4 doses of intranasal etripamil or placebo after an induced PSVT episode in an electrophysiology lab.
Conversion rates after 15 minutes were as high as 95% in patients receiving 140 mg of etripamil compared to 35% for patients receiving a placebo. Doses of 70 mg and 105 mg also produced statistically significant increases in conversion rate compared to placebo. The lowest dose, 35 mg, demonstrated a 65% conversion rate, which was not significant. Median time to PSVT conversion for all 4 doses of etripamil ranged from 1.82 to 3.03 minutes.
Miletone Chief Medical Officer Francis Plat commented, “Milestone Pharmaceuticals is committed to improving the lives of individuals with PSVT and we are highly encouraged by this Phase 2 data. The NODE-1 results are valuable in guiding further development of etripamil. We look forward to sharing the data with regulatory agencies as we finalize our Phase 3 development program. We thank all the investigators, the study site personnel and especially thank the patients for their contributions to the NODE-1 trial.”
Etripamil is a novel calcium channel antagonist, also known as MSP-2017. The compound was assigned the non-proprietary name “etripamil” in January 2016.
Read the Milestone Therapeutics press release.